Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenderitide in Heart Failure with Renal Impairment
NCT02603614Phase 2Completed
- Sponsor
- Capricor Therapeutics
- Start
- Dec 2015
- Primary completion
- Mar 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cenderitide in heart failure (HF), sponsored by Capricor Therapeutics. Primary endpoint: Safety and tolerability as evaluated by incidence and severity of treatment-emergent adverse events. Started Dec 2015; status: completed.
02
Drugs
cenderitide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT02603614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603614.